Product Description
The global tissue heart valve market was valued at $1.8 billion in 2025. This is expected to increase over the forecast period at a CAGR of 1.1% to reach $1.9 billion.
The full report suite on the global market for tissue heart valve includes stented, stentless and sutureless tissue heart valves.
The report includes data for 65 countries across 7 different regions which include North America, Latin America, Western Europe, Central & Eastern Europe, Middle East, Asia-Pacific, and Africa.
Data Types Included
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Procedure Numbers
- Market Drivers & Limiters
- Market Forecasts Until 2032, and Historical Data to 2022
- Recent Mergers & Acquisitions
- Company Profiles and Product Portfolios
- Leading Competitors
Tissue Heart Valve Market Trends
The use of conventional stented tissue heart valves is declining as transcatheter valve therapies and alternative surgical technologies gain broader adoption in clinical practice. Advances in minimally invasive procedures, particularly transcatheter aortic valve replacement (TAVR), have reduced reliance on traditional open surgical approaches, especially among elderly and high-risk patient populations. As these less invasive options continue to demonstrate favorable clinical outcomes and expand into lower-risk indications, they are increasingly replacing conventional stented tissue valves, a trend that is expected to persist over the forecast period.
Tissue Heart Valve Market Share Insights
- Edwards Lifesciences was the leader of the tissue heart valve market. Edwards Lifesciences offers its Carpentier-Edwards® line of surgical heart valves. Edwards Lifesciences’ aortic heart valve products are offered through its PERIMOUNT® product portfolio. Due to its global presence and established product line, Edwards Lifescinces is expected to maintain its market share over the forecast period.
- Medtronic was the second-leading competitor. The products Medtronic offers include the Hancock™, Mosaic™, Avalus™ and additional product lines. The Hancock™ and Mosaic™ stented tissue heart valves are used for aortic and mitral heart valve replacement. Since Medtronic has left the ventricular assist device market, it is expected that it will expand its presence in the heart valve segment. Medtronic launched its Avalus Ultra™ next-generation surgical aortic tissue valve in the U.S. in April 2024. This was followed by a commercial rollout in Western Europe in October 2024 and a subsequent launch in India in October 2025, expanding the company’s surgical aortic valve portfolio across the Asia-Pacific region. This phased geographic expansion underscores Medtronic’s strategy to broaden the global availability of its advanced tissue valve technologies.
- Abbott was the third-leading competitor globally in the tissue heart valve market in 2025. Its portfolio is now centered on the Epic™ mitral and aortic stented tissue valves, following the withdrawal of the Trifecta™ valve in 2023 due to early structural valve deterioration reports. This has weakened Abbott’s position, particularly in North America, and the company is not expected to gain significant market share over the forecast period amid strong competition from Edwards Lifesciences, Medtronic and Corcym.
Tissue Heart Valve Market Segmentation Summary
- Tissue Heart Valve Market – Further Segmented Into:
- Device Type: Stented, Stentless, Sutureless
Research Scope Summary
| Report Attribute | Details |
|---|---|
| Regions | North America (Canada, United States) Latin America (Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Guatemala, Mexico, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela) Western Europe (Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, United Kingdom) Central & Eastern Europe (Azerbaijan, Baltic States, Belarus, Bulgaria, Croatia, Czech Republic, Georgia, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Turkey, Ukraine) Middle East (Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates) Asia Pacific (Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Kyrgyzstan, Macao, Malaysia, Mongolia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, Uzbekistan, Vietnam) Africa (Algeria, Egypt, Ethiopia, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda) |
| Base Year | 2025 |
| Forecast | 2026-2032 |
| Historical Data | 2022-2024 |
| Quantitative Coverage | Procedure Numbers, Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
| Qualitative Coverage | Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
| Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
CONTACT US FOR ADDITIONAL INFORMATION
For full segmentation and any questions regarding research coverage, please contact us for a complimentary demo of the full report.
